Rottenstein Law Group Encouraged by $285,000 Fosamax Lawsuit Verdict in New York

The Rottenstein Law Group, which accepts clients who wish to file Fosamax injury lawsuits, is encouraged by the Feb. 5 report of a $285,000 verdict against Merck in a New York trial over the drug Fosamax, which has been found to weaken bones and cause jaw death.

 The Rottenstein Law Group, which accepts clients who wish to file Fosamax injury lawsuits, is encouraged by the Feb. 5 report of a $285,000 verdict against Merck in a New York trial over the drug Fosamax, which has been found to weaken bones and cause jaw death.

According to Reuters, the jury (In re: Scheinberg v. Merck & Co, Inc., U.S. District Court for the Southern District of New York, case no. 09-4119) found that Merck failed to warn plaintiff Rhoda Scheinberg’s doctors of potentially serious Fosamax side effects.* Scheinberg, 69, alleged that she had suffered delayed healing and disease in her jaw after a tooth extraction, both caused by Fosamax. This is the second verdict against Merck in a Fosamax trial. Previously, in a Manhattan court, a jury awarded Shirley Boles $8 million because she experienced “jaw death” while taking Fosamax, according to the story.

Read more: Rottenstein Law Group Encouraged by $285,000 Fosamax Lawsuit Verdict in New York

Rottenstein Law Group Heeds Fosamax MDL Court’s Order Designed to Weed Out Bad Cases

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is taking all necessary measures to comply with the latest order of the federal Fosamax MDL court.

New York (PRWEB) November 29, 2012

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is taking all necessary measures to comply with the latest order of the federal Fosamax MDL court.

As the United States District Court for the Southern District of New York prepares to wrap up the federal Fosamax multidistrict litigation matter In Re: Fosamax Products Liability Litigation (No. 06 MD 1789), Judge John F. Keenan has issued an order designed to weed out those cases “more likely to be dismissed… as they undergo closer scrutiny.” Defendant Merck & Co., Inc., manufacturer of the embattled osteoporosis drug, made a third request of the court for a so-called “Lone Pine” order. Judge Keenan had denied Merck’s previous requests, but he granted this one.

For more information read more on: Rottenstein Law Group Heeds Fosamax MDL Court’s Order Designed to Weed Out Bad Cases

Oferty i praca w Zarabiaj.pl

Various Uses of Bisphosphonate Drugs in Cancer Treatment

Described as a group of antiresorptive drugs, bisphosphonates are anti-bone loss medications that mainly function by intervening with the body’s natural bone cycle of breakdown and formation to slow down the rate of bone thinning, resulting to sustained or increased bone density and strength, health experts say. They are frequently used by people with osteoporosis, and are sometimes prescribed to people with osteopenia, lesser than usual bone mineral density, or those who face a higher risk of developing the bone disorder than others. However, as they have been proven effective in minimizing the risk of fractures in patients, Fosamax and other similar drugs have also been tied to a string of adverse effects, which in some instances, have paved the way for a series of lawsuits. The Fosamax Injury Lawsuit Center contains news and updates about Fosamax and related side effects.

 Bisphosphonates are also used to decrease pain and improve overall bone health in patients with metastasized cancer (cancer that has spread into neighboring sites of the affected area) especially to the bone, medical researchers say. There is also a growing body of evidence that suggests how bisphosphonates may impede further bony complications in metastatic malignant diseases and may even increase survival rate of patients suffering from myeloma with bone lesions.

 While they may be taken orally or administered intravenously, most oncologists choose the intravenous administration of bisphosphonates as it is done through a monthly short infusion and does not bring about gastrointestinal problems that most oral bisphosphonates have been associated with oral bisphosphonates. Two of the most commonly used bisphosphonates for metastasized cancer include Aredia with the chemical name pamidronate, and Zometa that goes by its generic equivalent zolendronic acid.

 Both manufactured and sold by pharmaceutical company Novartis, Aredia and Zometa are examples of bisphosphonates administered intravenously often used as treatment to hypercalcemia of malignancy (treat high levels of calcium in the blood related to cancer), myeloma, secondary breast and prostate cancer, as well as Paget\’s disease of the bone.

 Alendronate, popularly known by its trade name Fosamax, is an oral bisphosphonate drug by Merck & Co. While it is administered differently from Aredia and Zometa, it is also given to relieve bone pain in people suffering from metastatic bone cancer, multiple myeloma, and Paget’s disease of the bone.

 Along with the relief offered by these drug treatments are mild to severe side effects that may get better or worse over the course of treatment, according to medical experts. Experts recommend that patients take utmost precaution to possibly minimize their risk of experiencing these side effects and added health problems.

Sources:

drugs.com/mtm/aredia.html

cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/disodium-pamidronate

cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/zoledronic-acid

http://www.medicinenet.com/alendronate/article.htm

oncolink.org/types/article.cfm?c=1&s=89&ss=871&id=9629&CFID=54367541&CFTOKEN=94903688

orthoinfo.aaos.org/topic.cfm?topic=a00093

Premier Production of Oral Jelly Bisphosphonate by a Japanese Medical Establishment

Medical specialists and bone experts still believe that bisphosphonate, such as Merck’s Fosamax, is beneficial despite several association of serious adverse effects such as groin dislocation. An example of this is the recent market release of Bonalon Jelly of Japan’s Teijin Pharma Ltd. The 35mg alendronate sodium hydrate is comparable to Fosamax bisphosphonates 5 mg tablet. The Japanese pharmaceutical considers Bonalon Jelly to be more effective compared to other alendronate variations.Since oral jellies are easier to swallow and is more recognizable compared to tablets, Bonalon Jelly is expected to be more preferred by elderly patients. Most old patients needed to maintain several medicines daily, and because bisphosphonate should be medicated 30 minutes before or after any other medicine, having the bisphosphonate on jelly forms can help them keep up with their medications. The Jelly Bisphosphonate is also prescribed in one 35mg jelly a week.Even if Teijin Pharma claims that the drug is all right base from a ten-year product research, other studies from Japan and China were short lived in less than a year. Both the Japanese and Chinese researches have revealed similar results about the effectiveness of the 35mg weekly drug compared with the older tablet variant like 5mg Fosamax and other 70mg weekly dosage of alendronate.

Patients having bone problems should not anticipate that having the alendronate on jelly form. Talk to your doctors for a sure advice of prescription change and medical dose. To understand better and know more about this topic read Japanese Pharmaceutical Company Creates First Oral Jelly Bisphosphonate.